Coripharma Dossier List

Coripharma Dossier List
Product Description

We offer out-licensing of our own developed dossiers, along with a range of services that enable our customers to take products to their respective markets at the date of patent expiry and under their own brand. Currently we have over 20 own developed dossiers on our pipeline and our dossier list is readily available at our website.

Our services also include contract manufacturing from our widely audited and GMP-approved manufacturing site in Iceland.

Our manufacturing site is run solely on sustainable energy and we continue to limit our overall carbon footprint.

Read more Show less

Coripharma

  • IS
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Quality Service; Sustainability
  • Supplied from
    Iceland
More specifications Fewer specifications
Sales Markets
Show more Show less

Coripharma

  • IS
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company
View company profile

More Products from Coripharma (4)

  • Macitentan

    Product Macitentan

    Macitentan is a medicine that is used to treat Pulmonary arterial hypertension. Macitentan Film-coated tablets has one strength, 10mg, has passed its pivotal bioequivalence study and dossier is available.
    Our business development team remains available to discuss opportunities with our customers.
    ...
  • Eliglustat

    Product Eliglustat

    Is used to treat Gaucher disease which is a fat storage disorder. Eliglustat is available in 84mg hard capsules. Coripharma`s generic version of Eliglustat is being developed in our R&D facility located in Iceland, which is run solely on sustainable energy. We plan to have the dossier available in Q1 2...
  • Lisdexamfetamine

    Product Lisdexamfetamine

    Lisdexamfetamine is used to treat ADHD in children and adults. Lisdexamfetamine capsules come in six strengths, 20mg, 30mg, 40mg, 50mg, 60mg and 70mg. Pivotal BE study is completed and passing. Coripharma will finalize the dossier in Q4 2024 and start submitting for our clients in January 2025.
  • Ruxolitinib

    Product Ruxolitinib

    Ruxolitinib is used for the treatment of symptoms in adult patients with primary myelofibrosis which is a rare form of blood cancer. Ruxolitinib tablets come in four strengths, 5 mg, 10 mg, 15 mg and 20 mg. Pivotal BE study is completed and passing. Dossier is available and DCP slot confirmed in January 20...